New Patent Pool Deal For TB Drug Abandoned By Pfizer Could Spark Development

A new licensing deal between the Medicines Patent Pool and a leading academic center for a Phase II tuberculosis drug candidate originally in development by Pfizer could signal a real opportunity for getting a commercially challenging product to market. Public health groups, while welcoming the move, have noted that the deal is no guarantee that the medicine will actually reach the patients who need it, though.